Cancer Stem Cell News Volume 3.11 | Mar 26 2014


    Cancer Stem Cell News 3.11 March 26, 2014

    Cancer Stem Cell News

         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  Cancer Stem Cell News on Twitter

    Regulation of Colorectal Carcinoma Stemness, Growth and Metastasis by a miR-200c-Sox2 Negative Feedback Loop Mechanism
    The reduction of miR-200c increased the expression of colorectal carcinoma (CRC) stem cell markers and the sphere-forming capacity of CRC cell lines. Further study has shown that miR-200c and Sox2 reciprocally control their expression through a feedback loop. [Clin Cancer Res] Abstract
    FREE ALDEFLUOR™ Protocol Optimization Resource Pack – Get Yours

    PUBLICATIONS (Ranked by impact factor of the journal)
    CD133+ Tumor Initiating Cells (TIC) in a Syngenic Murine Model of Pancreatic Cancer Respond to Minnelide
    The authors isolated CD133+ cells from a spontaneous PDAC mouse model and studied both surface expression, molecular markers of pancreatic TIC. They also studied tumor initiation properties by implanting low numbers of CD133+ cells in immune competent mice. [Clin Cancer Res] Abstract

    Orchestration of Hepatocellular Carcinoma Development by Diverse Liver Cancer Stem Cells
    Scientists found that liver cancer stem cells defined by different markers show unique features of tumorigenicity and metastasis, with phenotypes closely associated with committed liver lineages. [J Gastroenterol] Abstract

    Comparative Expression Study of the Endo-G Protein Coupled Receptor (GPCR) Repertoire in Human Glioblastoma Cancer Stem-Like Cells, U87-MG Cells and Non Malignant Cells of Neural Origin Unveils New Potential Therapeutic Targets
    Researchers report a descriptive study of the differential expression of the endo-GPCR repertoire in human glioblastoma cancer stem-like cells, U-87 MG cells, human astrocytes and fetal neural stem cells. [PLoS One] Full Article

    Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138++ and CD138low Subpopulations in Multiple Myeloma Cell Lines
    The authors demonstrated the presence of two subpopulations – CD138++ (95-99%) and CD138low (1-5%) – in eight multiple myeloma cell lines. To find out possible stem-cell-like features, they phenotypically, genomically and functionally characterized the two subpopulations. [PLoS One] Full Article

    The Notch Pathway Is Important in Maintaining the Cancer Stem Cell Population in Pancreatic Cancer
    A gamma secretase inhibitor that inhibits the Notch pathway and a shRNA targeting the Notch target gene Hes1 were used to assess the role of the Notch pathway in cancer stem cell population maintenance and pancreatic tumor growth. [PLoS One] Full Article

    Tumor-Induced STAT3 Activation in Monocytic Myeloid-Derived Suppressor Cells Enhances Stemness and Mesenchymal Properties in Human Pancreatic Cancer
    Scientists demonstrated that monocytic myeloid-derived suppressor cells (CD11b+/Gr1+/Ly6G/Ly6Chi) significantly increase the frequency of ALDH1Bright cancer stem cells in a mouse model of pancreatic cancer. [Cancer Immunol Immunother] Full Article

    Stemness State Regulators SALL4 and SOX2 Are Involved in Progression and Invasiveness of Esophageal Squamous Cell Carcinoma
    SALL4 and SOX2 are two main transcription factors involved in maintenance of pluripotency, self-renewal and cell fate decision in embryonic stem cells. Investigators aimed to elucidate the expression levels of these important transcription factors in esophageal squamous cell carcinoma and to reveal their probable roles in maintenance and progression of the disease. [Med Oncol] Abstract

    A Mesenchymal Glioma Stem Cell Profile Is Related to Clinical Outcome
    Comparative analysis between glioma stem cells (GSCs) and H1 and H9 human embryonic stem cells as well as H9-derived neural stem cells indicates major variations in gene expression of pluripotency factors Nanog and OCT4, but a stable pattern for SOX2 suggesting its important function in maintaining pluripotency in GSCs. [Oncogenesis] Full Article

    Robust Growth of Human Mammary Luminal & Myoepithelial Cells with Serum-Free EpiCult-C (Human). Request a Free Sample

    The Paradigm of Mutant p53-Cancer Stem Cells and Drug Resistance
    The notion that p53 plays a regulatory role in the life of stem cells coupled with the observations that p53 mutations may contribute to the evolvement of cancer stem cells, makes it challenging to speculate that drug resistance and cancer recurrence are mediated by cancer stem cells expressing mutant p53. [Carcinogenesis] Abstract

    Glioblastoma Cancer Stem Cells: Biomarker and Therapeutic Advances
    Basic glioblastoma multiforme and glioblastoma cancer stem cell (GSC) genetics and proteomics studies combined with strategies to discover GSC-targeting agents could lead to novel treatments that significantly improve patient survival and quality of life. [Neurochem Int] Abstract

    Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

    BIT's 7th Annual World Cancer Congress-2014 (WCC2014)

    NRC and Zymeworks Partner to Develop Ground-Breaking Canadian Therapies for the Fight against Cancer
    The National Research Council of Canada (NRC) and Zymeworks Inc. announced a strategic collaborative agreement for a continued innovative business alliance. This three-year multi-million dollar agreement will focus on developing ground-breaking therapies for the fight against cancer, as well as inflammatory and autoimmune diseases. [Zymeworks Inc.] Press Release

    MultiCell Technologies Files U.S. and International Patent Applications for the Treatment of Liver Cancer
    MultiCell Technologies, Inc. has filed additional U.S. and international patent applications covering MCT-485 and its composition of matter, biological targets, mechanism of action, and methods and formulations for therapeutic use. MCT-485 is thought to target cancer by delivering a cytotoxic and oncolytic effect to only those cells having the highest tumor initiating capability that are part of the cancerous process such as cancer stem cells and tumor initiating cells. [PR Newswire Association LLC] Press Release

    From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.

    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    NEW BIT’s 7th Annual World Cancer Congress-2014 (WCC2014)
    May 16-18, 2014
    Nanjing, China

    NEW Society for Developmental Biology (SDB) 73rd Annual Meeting
    July 17-21, 2014
    Seattle, United States

    Visit our events page to see a complete list of events in the cancer stem cell community.

    NEW Postdoctoral Position – Stem Cells and Cancer (Brigham & Women’s Hospital – Harvard Medical School)

    Postdoctoral Fellow – Hematopoietic Stem Cell and Leukemia Research (City of Hope)

    Tenure-Track Faculty Position – Cancer Biology and Evolution (Moffitt Cancer Center)

    Postdoctoral Position – Glioblastoma, Oncolytic Virus and Cell Signaling (Ohio State University)

    Postdoctoral Research Fellow – Cancer Bioinformatics (Karolinska Institutet)

    Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

    Faculty Position – Cancer Biology and Evolution (Moffitt Cancer Center & Research Institute)

    Postdoctoral Position – Molecular Mechanisms of Cell Division (Memorial Sloan Kettering Cancer Center)

    Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

    Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

    Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

    Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


    Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

    Comments or Suggestions? Email Comments or suggestions? Submit your feedback here

    Learn more about Cancer Stem Cell News: Archives | Events | Contact Us